• MeiraGTx reported open-market sales by Stuart Naylor, chief scientific officer, ophthalmology, on July 7, 2026.
• Naylor sold 27,659 ordinary shares at weighted-average prices of USD 13.86 and USD 14.9.
• His direct holding fell to 640,846 ordinary shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MeiraGTx Holdings plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001742771-26-000012), on July 07, 2026, and is solely responsible for the information contained therein.